Conference Coverage
Conference Coverage
Longterm maintenance of PASI 75 responses observed with tildrakizumab
PARIS – More than 90% of PASI 75 responders to tildrakizumab at 6 months maintained at least a PASI 75 response at 148 weeks.
Conference Coverage
CONDOR trial: Most psoriasis patients can be downshifted to reduced-dose biologics
PARIS – Results of the first-ever randomized trial of biologic dose reduction in well-controlled psoriasis patients are reported.
Conference Coverage
Weight loss cuts risk of psoriatic arthritis
CHICAGO – An empowering new message for psoriasis patients.
Conference Coverage
Treating psoriasis with biologics: Recommendations from an expert
LAS VEGAS – A patient’s comorbidities can help focus the choice of a biologic.
Conference Coverage
Comorbidities are important in psoriasis care
LAS VEGAS – Cardiovascular comorbidities and psoriatic arthritis top the list of issues to keep an eye on.
Conference Coverage
Over one-third of psoriasis patients have PsA
And more top psoriasis posters from the Las Vegas Dermatology Seminar
Conference Coverage
Most dermatologic drugs safe for breastfeeding mothers
CHICAGO – Despite many physicians’ concerns, most dermatology drugs do not pose risks to the nursing infant or to...
Conference Coverage
IL inhibitor options move psoriasis treatment forward
Long-term data continue to support the safety and effectiveness of IL-17 and IL-23 inhibitor drugs.
Conference Coverage
Anti-TNF agents preferred for severe psoriasis in pregnancy
CHICAGO – Safety data supports anti-TNF agents first for systemic treatment of severe psoriasis in pregnancy,...
Latest News
Novel oral agent shows unprecedented efficacy in psoriasis
PARIS – Selective tyrosine kinase 2 inhibitor reached a 75% PASI 75 response rate in moderate to severe psoriasis at 12 weeks.